Finding the Right Heavy Chains for Immunostimulatory Antibodies
For twelve years, the oncology field has been revolutionized by antibodies targeting immune checkpoints. They must be considered as a heterogenous family of immunostimulatory antibodies displaying very different mechanisms of action, not only depending on the target or on the cells expressing it, bu...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/18/10367 |
| _version_ | 1797487440714268672 |
|---|---|
| author | Pierre Boulard Valérie Gouilleux-Gruart Hervé Watier |
| author_facet | Pierre Boulard Valérie Gouilleux-Gruart Hervé Watier |
| author_sort | Pierre Boulard |
| collection | DOAJ |
| description | For twelve years, the oncology field has been revolutionized by antibodies targeting immune checkpoints. They must be considered as a heterogenous family of immunostimulatory antibodies displaying very different mechanisms of action, not only depending on the target or on the cells expressing it, but also on the IgG subclass or IgG variant that has been chosen. To dissect this complex landscape, the clinical experience has been confronted with a precise analysis of the heavy chain isotypes, referred as new Ge nomenclature. For antibodies targeting inhibitory receptors, anti-CTLA-4 antibodies (whose main effect is to kill regulatory T cells) will be distinguished from anti-PD-1 antibodies and other true antagonistic antibodies. Antibodies targeting ligands of inhibitory receptors (PD-L1, CD47) represent another different category, due to the antigen expression on tumors and a possible beneficial killing effect. The case of agonistic antibodies targeting lymphocyte activatory receptors, such as CD40 or 4-1BB, is still another “under construction” category because these products are less advanced in their clinical development. Altogether, it appears that choosing the right heavy chain is crucial to obtain the desired pharmacological effect in patients. |
| first_indexed | 2024-03-09T23:47:40Z |
| format | Article |
| id | doaj.art-5ca0f364c46e4402956b211e44f63cae |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T23:47:40Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-5ca0f364c46e4402956b211e44f63cae2023-11-23T16:40:22ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-09-0123181036710.3390/ijms231810367Finding the Right Heavy Chains for Immunostimulatory AntibodiesPierre Boulard0Valérie Gouilleux-Gruart1Hervé Watier2EA7501, GICC, Faculté de Médecine, Université de Tours, F-37032 Tours, FranceEA7501, GICC, Faculté de Médecine, Université de Tours, F-37032 Tours, FranceEA7501, GICC, Faculté de Médecine, Université de Tours, F-37032 Tours, FranceFor twelve years, the oncology field has been revolutionized by antibodies targeting immune checkpoints. They must be considered as a heterogenous family of immunostimulatory antibodies displaying very different mechanisms of action, not only depending on the target or on the cells expressing it, but also on the IgG subclass or IgG variant that has been chosen. To dissect this complex landscape, the clinical experience has been confronted with a precise analysis of the heavy chain isotypes, referred as new Ge nomenclature. For antibodies targeting inhibitory receptors, anti-CTLA-4 antibodies (whose main effect is to kill regulatory T cells) will be distinguished from anti-PD-1 antibodies and other true antagonistic antibodies. Antibodies targeting ligands of inhibitory receptors (PD-L1, CD47) represent another different category, due to the antigen expression on tumors and a possible beneficial killing effect. The case of agonistic antibodies targeting lymphocyte activatory receptors, such as CD40 or 4-1BB, is still another “under construction” category because these products are less advanced in their clinical development. Altogether, it appears that choosing the right heavy chain is crucial to obtain the desired pharmacological effect in patients.https://www.mdpi.com/1422-0067/23/18/10367immunostimulatory antibodiesFc variantsantibody engineeringimmunoglobulin heavy chainstherapeutic antibodiesGe nomenclature |
| spellingShingle | Pierre Boulard Valérie Gouilleux-Gruart Hervé Watier Finding the Right Heavy Chains for Immunostimulatory Antibodies International Journal of Molecular Sciences immunostimulatory antibodies Fc variants antibody engineering immunoglobulin heavy chains therapeutic antibodies Ge nomenclature |
| title | Finding the Right Heavy Chains for Immunostimulatory Antibodies |
| title_full | Finding the Right Heavy Chains for Immunostimulatory Antibodies |
| title_fullStr | Finding the Right Heavy Chains for Immunostimulatory Antibodies |
| title_full_unstemmed | Finding the Right Heavy Chains for Immunostimulatory Antibodies |
| title_short | Finding the Right Heavy Chains for Immunostimulatory Antibodies |
| title_sort | finding the right heavy chains for immunostimulatory antibodies |
| topic | immunostimulatory antibodies Fc variants antibody engineering immunoglobulin heavy chains therapeutic antibodies Ge nomenclature |
| url | https://www.mdpi.com/1422-0067/23/18/10367 |
| work_keys_str_mv | AT pierreboulard findingtherightheavychainsforimmunostimulatoryantibodies AT valeriegouilleuxgruart findingtherightheavychainsforimmunostimulatoryantibodies AT hervewatier findingtherightheavychainsforimmunostimulatoryantibodies |